Infection Outcomes in Infant of hepatitis B Virus Infected Mother Receiving Tenofovir during Pregnancy in Sakon Nakhon Hospital

Abstract

               This retrospective descriptive research aimed to study the incidence of mother–to–child transmission of hepatitis B Virus (HBV) and immunity development after HBV vaccination in 19 children born to mothers with HBV infection, high viremia and receiving tenofovir disoproxil fumarate (TDF) during pregnancy and receiving antenatal care (ANC) service and delivery at Sakon Nakhon hospital from 1st October 2017 to 30th September 2020. This hospital medical records and antenatal care database were retrieved. The research tool was data collection form. Data were analyzed using the descriptive statistics.

              The results revealed that eighty–nine point five percent of mothers with HBV infection and high viremia was received TDF for more than 4 weeks before delivery. Most of them did not test for Hepatitis B surface antibody (HBsAb) during pregnancy (94.7%) and viral load after receiving TDF (89.5%). However, all of their newborns had received hepatitis B immunoglobulin (HBIG) within 12 hours after birth (100%). Most children were tested for hepatitis B surface antigen (HBsAg) and HBsAb when they aged 12–24 months (84.2%). The incidence of HBV infection and immunity development to HBV were 10.5% and 78.9%, respectively.

                This study was the outcome of overall operation to eliminate mother–to–child transmission of HBV according to the Ministry of Public Health policy in only pregnant woman with HBV infection, high viremia and receiving TDF. Therefore, the further study should be carried out in other pregnant women with HBV infection or who did not receive ANC service.

                Keywords: Mother–to–child transmission of hepatitis Bvirus, Hepatitis B immunoglobulin (HBIG), Tenofovir disoproxil fumarate (TDF)